MAGE-A4 antigen-specific TCR modified lymphocytes (Takara Bio)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameMAGE-A4 antigen-specific TCR modified lymphocytes (Takara Bio)
Drug Alias NameMAGE-A4 antigen-specific RetroNectin TCR gene therapyMAGE-A4-targeted T-cell therapy (Takara Bio)MAGE-A4 TCR-transduced T-cell therapy (Takara Bio)TBI-1201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunostimulantsMelanoma-associated antigen 4 modulatorsGene transference
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakara Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakara Bio IncMie University
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A